STABLE CANNABINOID FORMULATIONS
The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.
1 . A stable pharmaceutical formulation for oral administration comprising:
from about 0.1 to about 40% of a cannabinoid; and from about 10 to about 95% of a lipid.
2 . The formulation of claim 1 wherein the lipid is selected from the group consisting of sesame oil, olive oil, corn oil, sunflower oil, safflower oil, flaxseed oil, almond oil, peanut oil, walnut oil, cashew oil, castor oil, coconut oil, palm oil, soybean oil, canola oil, vegetable oil, rice bran oil, caproic acid, enanthic acid, caprylic acid, pelargonic acid, capric acid, undecylenic acid, lauric acid, myristic acid, pentadecylic acid, palmitic acid, margaric acid, oleic acid, stearic acid, nonadecylic acid, linoleic acid, arachidic acid and arachidonic acid, medium chain glycerides, decanoyl glycerides, octanoyl glycerides, caprylic/capric triglyceride, oleoyl polyoxyl-6 glycerides, linoleoyl polyoxyl-6 glycerides, polyglyceryl-3 dioleate, glyceryl monolinoleate, glyceryl monocaprylate, oleic acid, and a combination thereof.
3 . The formulation of claim 1 wherein the cannabinoid is selected from group consisting of cannabinol, cannabidiol, dronabinol (delta-9-tetrahydrocannabinol), delta-8-tetrahydrocannabinol, 11-hydroxy-tetrahydrocannabinol, 11-hydroxy-delta9-tetrahydrocannabinol, levonantradol, delta-11-tetrahydrocannabinol, tetrahydrocannabivarin, amandamide, nabilone, acids, analogs, and synthetic derivatives thereof.
4 . The formulation of claim 3 wherein the cannabinoid is cannabidiol.
5 . The formulation of claim 4 wherein the cannabidiol is substantially pure, synthetically synthesized, cannabidiol which has a purity greater than 98%.
6 . The formulation of claim 1 wherein the formulation is free of alcohol.
7 . The formulation of claim 1 further comprising from about 1% to about 15% ethanol.
8 . The formulation of claim 7 wherein the ethanol is at a concentration from about 1% to about 10%.
9 . The formulation of claim 1 further comprising from about 0.001% to about 1% of an antioxidant.
10 . The formulation of claim 9 wherein the antioxidant is selected from the group consisting of butylated hydroxytoluene, butylated hydroxyl anisole, alpha-tocopherol (Vitamin E), ascorbyl palmitate, ascorbic acid, sodium ascorbate, ethylendiamino tetraacetic acid (EDTA), cysteine hydrochloride, citric acid, sodium citrate, sodium bisulfate, sodium metabisulfite, lecithin, propyl gallate, sodium sulfate, monothioglycerol, tert-butylhydroquinone and combinations thereof.
11 . The formulation of claim 10 wherein the antioxidant is selected from the group consisting of butylated hydroxytoluene, butylated hydroxyl anisole, alpha tocopherol (Vitamin E), ascorbyl palmitate, propyl gallate, EDTA, tert-butylhydroquinone and a combination thereof.
12 . A stable pharmaceutical formulation for oral administration comprising:
from about 5% to about 40% of cannabidiol; and
from about 10 to about 74% of a medium chain glyceride.
13 . The formulation of claim 12 wherein the formulation is free of alcohol.
14 . The formulation of claim 12 further comprising from about 1% to about 15% ethanol.
15 . The formulation of claim 12 further comprising from about 0.1% to about 1.0% of an antioxidant selected from the group consisting of alpha-tocopherol (Vitamin E), ascorbyl palmitate, and a combination thereof.
16 . The formulation of claim 12 wherein:
the cannabidiol is at a concentration of from about 28% to about 32%;
the medium chain triglyceride is at a concentration from about 66% to about 74%.
17 . The formulation of claim 16 , wherein the medium chain triglyceride is a caprylic/capric triglyceride.
18 . A stable pharmaceutical formulation for oral administration comprising:
cannabidiol at a concentration of about 31.09%; and
caprylic/capric triglyceride at a concentration of about 68.4%
19 . The formulation of claim 18 further comprising about 0.20% alpha-tocopherol (Vitamin E).
20 . A method for treating a disease or disorder, or a symptom of a disease or disorder, comprising administering the formulation of claim 1 to a patient in need thereof, wherein the disease or disorder is selected from the group consisting of Prader-Willi syndrome, obesity, graft versus host disease, gelastic seizures/hypothalamic hamartoma, neonatal seizures, movement disorders including dystonia, central pain syndromes, phantom limb pain, multiple sclerosis, traumatic brain injury, radiation therapy, acute and chronic graft versus host disease, T-cell autoimmune disorders, colitis, Dravet Syndrome, Lennox Gastaut Syndrome, mycolonic seizures, juvenile mycolonic epilepsy, refractory epilepsy, schizophrenia, juvenile spasms, West syndrome, infantile spasms, refractory infantile spasms, tuberous sclerosis complex, brain tumors, neuropathic pain, cannabis use disorder, post-traumatic stress disorder, anxiety, early psychosis, Alzheimer's Disease, autism, acne, Parkinson's disease, social anxiety disorder, depression, diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, ischemic injury of heart, ischemic injury of brain, chronic pain syndrome, and rheumatoid arthritis.
21 . The method of claim 20 , wherein the patient is in a fed or fasted condition.
22 . A method for assisting with withdrawal from opioids, cocaine, heroin, amphetamines or nicotine comprising administering the formulation of claim 1 to a patient in need thereof.